Search

everythinglearnresearchcommunity

for

Search:↓

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

A trial showed that a new treatment is safe and effective for male pattern baldness, with most participants growing new hair.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Retinoids may help treat lupus nephritis and reduce steroid use.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

The combination treatment showed a higher response rate but no significant survival benefits.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Weekly bicalutamide is safe and effective, with 50 mg/week recommended.

ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.

Guselkumab significantly improves psoriasis symptoms within 12 weeks.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Temozolomide improves survival in grade III glioma patients without harming quality of life.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.

The data suggests that dosing differences can help manage spasticity in patients with upper motor neuron dysfunction.

Injections of special skin cells showed potential in treating hair loss, with some participants experiencing increased hair density.